Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 799 GBX -0.55% Market Closed
Market Cap: 4B GBX
Have any thoughts about
Hikma Pharmaceuticals PLC?
Write Note

Hikma Pharmaceuticals PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hikma Pharmaceuticals PLC
Revenue Peer Comparison

Comparables:
GSK
AZN
VRNA
INDV
DPH

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Hikma Pharmaceuticals PLC
LSE:HIK
Revenue
$3B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
7%
GlaxoSmithKline PLC
LSE:GSK
Revenue
ÂŁ31.4B
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
3%
AstraZeneca PLC
LSE:AZN
Revenue
$49.1B
CAGR 3-Years
18%
CAGR 5-Years
16%
CAGR 10-Years
6%
Verona Pharma PLC
NASDAQ:VRNA
Revenue
$5.6m
CAGR 3-Years
-48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Indivior PLC
LSE:INDV
Revenue
$1.1B
CAGR 3-Years
17%
CAGR 5-Years
4%
CAGR 10-Years
0%
Dechra Pharmaceuticals PLC
LSE:DPH
Revenue
ÂŁ761.5m
CAGR 3-Years
14%
CAGR 5-Years
13%
CAGR 10-Years
15%

See Also

What is Hikma Pharmaceuticals PLC's Revenue?
Revenue
3B USD

Based on the financial report for Jun 30, 2024, Hikma Pharmaceuticals PLC's Revenue amounts to 3B USD.

What is Hikma Pharmaceuticals PLC's Revenue growth rate?
Revenue CAGR 10Y
7%

Over the last year, the Revenue growth was 10%. The average annual Revenue growth rates for Hikma Pharmaceuticals PLC have been 8% over the past three years , 7% over the past five years , and 7% over the past ten years .

Back to Top